Stock Research for ELGX

ELGX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ELGX Stock Chart & Research Data

The ELGX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ELGX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ELGX Due diligence Resources & Stock Charts

The ELGX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ELGX Detailed Price Forecast - CNN Money CNN View ELGX Detailed Summary - Google Finance
Yahoo View ELGX Detailed Summary - Yahoo! Finance Zacks View ELGX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ELGX Trends & Analysis - Trade-Ideas Barrons View ELGX Major Holders - Barrons
NASDAQ View ELGX Call Transcripts - NASDAQ Seeking View ELGX Breaking News & Analysis - Seeking Alpha
Spotlight View ELGX Annual Report - CompanySpotlight.com OTC Report View ELGX OTC Short Report - OTCShortReport.com
TradeKing View ELGX Fundamentals - TradeKing Charts View ELGX SEC Filings - Bar Chart
WSJ View Historical Prices for ELGX - The WSJ Morningstar View Performance/Total Return for ELGX - Morningstar
MarketWatch View the Analyst Estimates for ELGX - MarketWatch CNBC View the Earnings History for ELGX - CNBC
StockMarketWatch View the ELGX Earnings - StockMarketWatch MacroAxis View ELGX Buy or Sell Recommendations - MacroAxis
Bullish View the ELGX Bullish Patterns - American Bulls Short Pains View ELGX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ELGX Stock Mentions - StockTwits PennyStocks View ELGX Stock Mentions - PennyStockTweets
Twitter View ELGX Stock Mentions - Twitter Invest Hub View ELGX Investment Forum News - Investor Hub
Yahoo View ELGX Stock Mentions - Yahoo! Message Board Seeking Alpha View ELGX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ELGX - SECform4.com Insider Cow View Insider Transactions for ELGX - Insider Cow
CNBC View ELGX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ELGX - OTC Markets
Yahoo View Insider Transactions for ELGX - Yahoo! Finance NASDAQ View Institutional Holdings for ELGX - NASDAQ


Stock Charts

FinViz View ELGX Stock Insight & Charts - FinViz.com StockCharts View ELGX Investment Charts - StockCharts.com
BarChart View ELGX Stock Overview & Charts - BarChart Trading View View ELGX User Generated Charts - Trading View




Latest Financial News for ELGX


Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Posted on Friday January 11, 2019

Endologix, Inc. (ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to a newly hired executive (the “Awardee”). The awards were approved by the Company’s Compensation Committee, which is comprised of independent Directors, on December 10, 2018, as an inducement material to the Awardee’s entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4). The inducement grants to the Awardee consisted of (i) options (the “Options”) to purchase up to an aggregate of 250,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at an exercise price of $0.64 per share, and (ii) 150,000 restricted stock units (the “RSUs”).


Endologix Appoints John D. Zehren as Chief Commercial Officer
Posted on Thursday January 10, 2019

Endologix, Inc. (ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D. Zehren as the Company’s Chief Commercial Officer, effective as of January 7, 2019 (the “Effective Date”). Mr. Zehren brings to Endologix more than twenty years of commercial, sales and marketing, and business development experience in the medical device industry. Earlier in his distinguished career, Mr. Zehren spent over a decade at Edwards Lifesciences, the last four years of which were in the role of Vice President of Sales and Marketing.


Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance
Posted on Monday January 07, 2019

Endologix, Inc. (the “Company”) (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be approximately $34 million. The Company reaffirms its previously issued annual guidance and continues to expect 2019 revenue of at least $140 million. The Company anticipates revenue for the first quarter ending March 31, 2019 of approximately $35 million.


Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications
Posted on Friday January 04, 2019

Endologix® Inc. (ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that in order to ensure optimal outcomes for patients, unrestricted sales and use of the Nellix System will cease immediately, and the product will only be available for use under clinical protocol with pre-screened patients that adhere to the current indications. “We monitor the performance of the Nellix System through clinical trials, our complaint monitoring system, physician interaction and available publications,” said Dr. Matt Thompson, Chief Medical Officer of Endologix.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.